The closing price of Guardant Health Inc (NASDAQ: GH) was $20.14 for the day, up 3.71% from the previous closing price of $19.42. In other words, the price has increased by $+0.72 from its previous closing price. On the day, 3700730 shares were traded.
Ratios:
Our analysis of GH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.24 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 8.53 whereas as Long-Term Debt/Eq ratio is at 8.36.
Raymond James Upgraded its Mkt Perform to Outperform on November 13, 2023, while the target price for the stock was maintained at $27.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 04 when Joyce Meghan V. sold 100 shares for $26.34 per share. The transaction valued at 2,634 led to the insider holds 4,422 shares of the business.
Kalia Kumud sold 5,800 shares of GH for $152,954 on Dec 01. The Chief Information Officer now owns 5,926 shares after completing the transaction at $26.37 per share. On Sep 12, another insider, Kalia Kumud, who serves as the Chief Information Officer of the company, sold 2,125 shares for $32.59 each. As a result, the insider received 69,254 and left with 7,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2.45B and an Enterprise Value of 2.64B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.35 while its Price-to-Book (P/B) ratio in mrq is 15.44. Its current Enterprise Value per Revenue stands at 4.67 whereas that against EBITDA is -6.08.
Stock Price History:
Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $19.10. The 50-Day Moving Average of the stock is 24.44, while the 200-Day Moving Average is calculated to be 29.61.
Shares Statistics:
GH traded an average of 1.52M shares per day over the past three months and 1.8M shares per day over the past ten days. A total of 121.63M shares are outstanding, with a floating share count of 115.89M. Insiders hold about 4.78% of the company’s shares, while institutions hold 92.19% stake in the company. Shares short for GH as of Jan 31, 2024 were 5.54M with a Short Ratio of 3.64, compared to 5.23M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.57% and a Short% of Float of 4.76%.
Earnings Estimates
The firm’s stock currently is rated by 18 analysts. On average, analysts expect EPS of -$0.81 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$1.04, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.62 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.46 and -$3.81 for the fiscal current year, implying an average EPS of -$3.11. EPS for the following year is -$2.82, with 20 analysts recommending between -$1.85 and -$3.48.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 19 analysts. It ranges from a high estimate of $161.9M to a low estimate of $147M. As of the current estimate, Guardant Health Inc’s year-ago sales were $128.71M, an estimated increase of 17.20% from the year-ago figure. For the next quarter, 19 analysts are estimating revenue of $161.08M, an increase of 17.40% over than the figure of $17.20% in the same quarter last year. There is a high estimate of $166.58M for the next quarter, whereas the lowest estimate is $155.3M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $680.29M, while the lowest revenue estimate was $646.4M, resulting in an average revenue estimate of $664.64M. In the same quarter a year ago, actual revenue was $563.95M, up 17.90% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $806.77M in the next fiscal year. The high estimate is $869.9M and the low estimate is $760.6M. The average revenue growth estimate for next year is up 21.40% from the average revenue estimate for this year.
